Shares of Oramed are down 73% or $7.92 in pre-market trading at $2.87. Last night, the company announced that the top-line results from its Phase 3 clinical trial comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes at 26 weeks did not meet its primary endpoint. The stock has also been downgraded to Hold at Canaccord this morning.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ORMP:
- Oramed downgraded to Hold at Canaccord after ORMD-0801 discontinued
- Oramed downgraded to Hold from Buy at Canaccord
- Oramed Crashes after Disappointing Topline Results
- Oramed’s results from phase 3 trial of ORMD-0801 did not meet primary endpoint
- Oramed granted combination therapy patent for treating diabetes